EverHint Signal — Momentum Swing: Breakout Standard — December 08, 2025

What This Signal Is (Quick)

Momentum Swing — Breakout Standard looks for stocks that are:

• Trading within ~3% of their 52-week high
• Showing volume ≥ ~1.5× their 20-day dollar average
• Confirming short-term momentum with supportive trend structure

The idea: catch momentum continuation breakouts that are already attracting institutional attention, then ride the move for 1–4 weeks (classic swing timeframe).

This is an experimental scanner, based on publicly available data, and is intended for research, back-testing, and watchlist building — not for blind entries.

For 2025-12-08 this breakout scanner surfaced 23 candidates across healthcare, technology, financials, and consumer names.

How We Ranked Today (Reader Version)

For this report the list is ranked by Score:

• Score (0–100) – EverHint composite quality ranking (higher = stronger overall breakout profile)
• Volume Thrust – Ratio vs 20-day average dollar volume (e.g., 2.0x = 100% above normal)
• % of 52W High – How close today’s close is to the 52-week high

Additional overlays in the commentary:

• Insider Net (USD) – 90-day open-market P vs S (purchases minus sales)
• Days → ER – Days until next earnings (where available)

Signals here are for education and back-testing. You still need your own entries, stops, and position sizing.

🚀 Breakout Signals (Ranked by Score)

How to read the table:

• Vol Thrust – Liquidity + participation. 2.0x = twice the recent 20-day average dollar volume.
• % of 52W High – How close price is to the 52-week high; 100% = at/around the high.
• Score – Composite breakout quality (0–100). Higher = stronger all-around setup.
• Insider Net (USD) – 90-day open-market buying minus selling (P vs S only).
• Days → ER – Days until the next scheduled earnings (where available).

Field Notes on the Stronger Setups

• Healthcare cluster:
  • ARWR, APGE, NRIX, IDYA, KRYS, KYMR, PTGX, OCUL, AKRO – heavy representation. A lot of biotech/therapeutics momentum sitting right at 52-week highs with solid volume thrust.
  • Several of these show net insider selling (ARWR, NRIX, KYMR, PTGX, AKRO), which doesn’t invalidate momentum but suggests sizing and holding periods should be conservative.
• Quality large/mid-caps:
  • LUV, FITB, STT, IVZ – classic liquid names with improving momentum and volume >1.5x. These tend to be more “institutional-friendly” breakouts.
  • LUV and STT have relatively modest scores compared to the biotech leaders but benefit from depth and tighter spreads.
• High-octane volume thrust:
  • KYMR, WBD, INDV, OCUL, GPCR, AKRO show outsized volume thrust (4–9x). These can move fast both ways — ideal for active swing traders, not for passive investors.
• Event risk (earnings):
  • Most names have ~40–85 days to earnings, which roughly lines up with the 1–4 week holding window.
  • A few tickers (e.g., DG, ZTO) have no upcoming earnings date in this window, making them more “pure technical” trades in the near term.

Recent Headlines Around Key Breakouts

(Links cleaned of tracking where possible.)

• ARWR – Arrowhead Pharmaceuticals, Inc.
  • Announces initiation of an early-stage study targeting tau-related diseases, including Alzheimer’s – strong narrative backing the breakout.
  • Notable institutional interest reported via 13F filings, reinforcing the higher end of the score range.
• APGE – Apogee Therapeutics, Inc.
  • Presents at a major healthcare conference, keeping the story in front of institutions and fueling interest near the highs.
• IVZ – Invesco Ltd.
  • Coverage on a potential “modern makeover” for a flagship ETF lineup, putting a spotlight on the brand and flows.
  • Recent analyst commentary frames the stock around a “Hold” consensus, but the technicals show accumulation.
• PTGX – Protagonist Therapeutics, Inc.
  • Institutional buyers reported building new positions.
  • Longer-term data updates in hematology continue supporting the fundamental backdrop, dovetailing with the technical breakout.
• OCUL – Ocular Therapeutix, Inc.
  • Stock spiked sharply after a faster-than-expected regulatory path headline for a vision-related therapy.
  • Follow-up corporate grant/inducement news confirms ongoing development activity behind the move.
• DG – Dollar General Corporation
  • Mentioned across multiple market recaps and “scorecard” style pieces as a recession-resilient retailer; breakout sits just below the 52W high with solid volume and defensive flavor.

(As always, headlines are context, not trade triggers.)

Field Notes: Strategy & Sector Rotation

• Breakout structure:
  • Almost all names are above their 50- and 200-day moving averages and hugging 52-week highs — classic momentum continuation structure.
  • Volume thrust above 1.5x adds a confirmation layer that these aren’t just illiquid pops.
• Sector flavor:
  • Healthcare dominates the list, followed by Technology and Financial Services.
  • Consumer names (VSCO, DG) and Comm Services (WBD) show that rotation is not purely defensive; there’s clear appetite for higher-beta breakout ideas in specific pockets.
• Risk markers:
  • Several high-score names carry negative insider net flows, which is a yellow flag rather than a hard “no.”
  • High volume thrust names (e.g., GPCR, KYMR, OCUL) can overshoot both up and down — stop placement and position sizing matter more than usual.

Vlad’s Take (EverHint)

On 2025-12-08, the overall backdrop leaned mild risk-off:

• S&P 500 (^GSPC): -0.42%
• Dow (^DJI): -0.48%
• Nasdaq (^IXIC): -0.38%
• Russell 2000 (^RUT): -0.45%

Small-caps moved roughly in line with large-caps, so there wasn’t a huge breadth divergence — more of a uniform, modest pullback.

The VIX closed around 16.66 (about +3.16% on the day), which is normal to slightly elevated volatility: not a fear spike, but enough to reward tighter risk management.

In crypto, BTC-USD gained about +0.77% and ETH-USD about +2.45%, showing that risk appetite hasn’t vanished across the board. The 10-year yield (^TNX) sits near 4.17% (+0.65%), a small uptick that still keeps some pressure on rate-sensitive names.

What this means for Breakout Standard:

• I’d favor tiered entries (e.g., partial at breakout, partial on pullback) instead of all-in at the highs.
• In healthcare and other high-beta sectors, I’d lean toward shorter holding windows and tighter initial stops, widening only if the breakout behaves well.
• Large, liquid names (LUV, FITB, STT, IVZ, DG) can serve as “core swing” candidates, while the smaller biotech names are more like “satellite” trades around that core.

As always, this scanner is a shortlist generator. The heavy lifting — your entries, exits, risk per trade, and portfolio construction — is still on you.

Independent, data-driven signals.
No hype. No promotions. Absolutely Zero bias. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/

✨ If this clarity helped your research, liking, sharing, or subscribing helps keep this project strong.